Inflammatory keratitis and trastuzumab in the context of breast cancer - a case report

Author:

Tremblay Anthony1,Joseph Rosa-Li2

Affiliation:

1. Clinique de l'oeil d'Alma

2. Université de Sherbrooke

Abstract

Abstract

Purpose: This case report aims to provide a comprehensive description of the presentation of a subepithelial inflammatory keratitis observed in a patient undergoing trastuzumab treatment. Study Design: Case report and review of the literature. Methods: To conduct a literature review, we used the ScienceDirect (Elsevier) and PubMed databases. Background: Trastuzumab is a molecule commonly employed in the treatment of breast cancer. It is principally known for its cardiotoxic adverse effects (1) (2); however, recent literature has started to shed light on potential ocular adverse effects associated with its use (2) (3) (4) (5) (6) (7) (8). Therefore, this case report details the experience of a female patient who underwent treatment with this molecule and subsequently developed an inflammatory keratitis. Case presentation: A 63-year-old female diagnosed with breast cancer, presented corneal haze, corneal edema, epithelial folds, and reduction of visual acuity following cataract surgery. A diagnosis of subepithelial inflammatory keratitis was established. A causal relationship was identified between the corneal inflammation and the trastuzumab, as evidenced by the amelioration of symptoms upon discontinuation of treatment. Diagnosis: Corneal haze was the first clinical sign of keratitis observed and it appeared approximately one month following cataract surgery. A Herpes simplex virus (HSV) keratitis was suspected and excluded after a negative polymerase chain reaction (PCR) and unsuccessful antiviral treatment. The keratitis was initially controlled with a topical 1% prednisolone acetate, but it recurred upon tapering. The patient eventually experienced a severe recurrence that did not respond to oral prednisone. This led to discontinuation of trastuzumab for several weeks, resulting in the resolution of inflammation even after tapering oral prednisone and topical 1% prednisolone. Conclusion: The antineoplastic agent trastuzumab carries notable ocular risks such as subepithelial inflammatory keratitis as evidenced by this case report and the literature.

Publisher

Springer Science and Business Media LLC

Reference15 articles.

1. Beaudet J, Poirier M, Goulet S. Guided’utilisationdutrastuzumab(HerceptinMC)dansletraitementadjuvantducancerdusein[Internet].Comitédel’évolutiondespratiquesenoncologie(CEPO);2008[cited2023Sept23]availablefrom:https://www.msss.gouv.qc.ca/inc/documents/ministere/lutte-contre-le-cancer/guides-cepo-pdf/CEPO-Trastuzumab_et_traitement_adjuvant_du_cancer_du_sein-_mise_à_jour_(2008-02).pdf.

2. Trastuzumab-Induced Corneal Ulceration: Successful No-Drug Treatment of a ‘Blind’ Side Effect in a Case Report;Orlandi A;BMC Cancer,2015

3. Retinal Toxicities of Systemic Anticancer Drugs;Arora S;Surv Ophthalmol

4. Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist;Canino F;Clin Breast Cancer

5. Emergence of Ocular Toxicities Associated with Novel Anticancer Therapeutics: What the Oncologist Needs to Know;Ali A;Cancer Treat Rev

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3